Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495867 | 0.91 | ALOX5 (0.58) | ALOX5TRPA1KDM4ENPSR1KIF11 | |
| SCHEMBL26577416 | 0.85 | TDP1 (0.50) | ALOX5TRPA1KDM4ESMN1; SMN2CYP2C9 | |
| SCHEMBL9494429 | 0.85 | PABPC1 (0.54) | KDM4ESMN1; SMN2KMT2ATP53CA12 | |
| SCHEMBL17978231 | 0.85 | CA12 (0.46) | ALOX5TRPA1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL10513235 | 0.83 | NOX1 (0.55) | KDM4ECYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL26114462 | 0.81 | ALOX5 (0.50) | ALOX5KMT2ATSHRPOLBTDP1 | |
| SCHEMBL9511152 | 0.81 | KDM4E (0.52) | KDM4ENPSR1KIF11SMN1; SMN2CYP1A2 | |
| SCHEMBL18288011 | 0.81 | ALOX5 (0.68) | ALOX5TRPA1KDM4EKIF11SMN1; SMN2 | |
| SCHEMBL30572037 | 0.80 | KDM4E (0.46) | KDM4ENPSR1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL9496310 | 0.76 | PABPC1 (0.51) | KDM4ESMN1; SMN2KMT2ATP53CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-0267794-B1 | PROCESS FOR PREPARING POLYOLEFINS | Nippon Petrochemicals Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| EP-0052471-B1 | PROCESS AND CATALYST FOR POLYMERIZATION OF OLEFINS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4526941-A | Contacting alpha olefin with catalyst comprising organomagnesium compound, titanium compound, nitrogen or sulfur heterocyclic compound, slurry component and organometallic component | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-07-02 | — | — | US | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0052471-A1 | Process and catalyst for polymerization of olefins | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | ALOX5 193/4885TRPA1 2950/4885KDM4E 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.